查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1966014

全球血漿分離市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Plasma Fractionation Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 167 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計血漿分餾市場將從 2025 年的 441.8 億美元成長到 2034 年的 965.2 億美元，2026 年至 2034 年的複合年成長率為 9.07%。

全球血漿分離市場正穩定成長，主要受用於治療免疫力缺乏、出血性疾病和神經系統疾病的血漿衍生療法需求不斷成長的推動。血漿分離技術可將血漿分離成其主要蛋白質成分，例如免疫球蛋白、白蛋白和凝血因子。慢性病和罕見病患疾病的上升也顯著推動了市場需求。

關鍵成長要素包括生物技術的進步、血漿採集基礎設施的改善以及人們對血漿療法的認知不斷提高。政府對血漿捐獻計畫的支持以及開發中國家醫療保健系統的擴展進一步提升了市場前景。持續的研發工作正在改善純化技術並提高生產效率。

展望未來，隨著治療應用範圍的擴大和全球醫療保健支出的成長，市場預計將持續成長。它將在新興經濟體中發揮更關鍵的作用，擴大病患的用藥途徑。分餾技術的創新和監管規範的統一有望進一步增強該行業的長期發展前景。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球血漿分離市場：依產品分類

  • 市場分析、洞察與預測
  • 白蛋白
  • 免疫球蛋白（靜脈注射免疫球蛋白、皮下注射免疫球蛋白及其他免疫球蛋白）
  • 凝血因子（因子VIII、因子IX、血管性血友病因子、凝血酶原複合物濃縮物、纖維蛋白原濃縮物等）
  • 蛋白酶抑制劑
  • 其他

第5章：全球血漿分離市場：依方法分類

  • 市場分析、洞察與預測
  • 離心分離
  • 深度過濾
  • 層析法
  • 其他

第6章 全球血漿分離市場：依應用分類

  • 市場分析、洞察與預測
  • 神經病學
  • 血液學
  • 腫瘤學
  • 免疫學
  • 肺科
  • 其他

第7章：全球血漿分離市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 臨床研究
  • 其他

第8章 全球血漿分離市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Grifols SA
    • CSL Limited
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Kedrion SPA
    • LFB SA
    • Biotest AG
    • Sanquin
    • Bio Products Laboratory Ltd
    • Intas Pharmaceuticals Ltd
簡介目錄
Product Code: VMR11210047

The Plasma Fractionation Market size is expected to reach USD 96.52 Billion in 2034 from USD 44.18 Billion (2025) growing at a CAGR of 9.07% during 2026-2034.

The Global Plasma Fractionation Market has witnessed steady growth driven by increasing demand for plasma-derived therapies used in treating immune deficiencies, bleeding disorders, and neurological conditions. Plasma fractionation involves separating plasma into its key protein components such as immunoglobulins, albumin, and clotting factors. Rising prevalence of chronic and rare diseases has significantly boosted market demand.

Major growth drivers include advancements in biotechnology, improved plasma collection infrastructure, and growing awareness of plasma-based treatments. Government support for plasma donation programs and expansion of healthcare systems in developing countries further enhance market prospects. Continuous R&D efforts are improving purification techniques and production efficiency.

Looking forward, the market is expected to grow as therapeutic applications expand and global healthcare spending increases. Emerging economies will play a crucial role due to expanding patient access. Innovations in fractionation technology and regulatory harmonization will further strengthen the industry's long-term outlook.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

  • Albumin
  • ImmunoglobulinsA ((Intravenous immunoglobulins, Subcutaneous immunoglobulins, Other immunoglobulins))
  • Coagulation FactorsA (Factor VIII, Factor IX, VON Willebrand Factor, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others)
  • Protease inhibitors
  • Others

By Method

  • Centrifugation
  • Depth Filtration
  • Chromatography
  • Others

By Application

  • Neurology
  • Hematology
  • Oncology
  • Immunology
  • Pulmonology
  • Others

By End-use

  • Hospitals & Clinics
  • Clinical Research
  • Others

COMPANIES PROFILED

  • Grifols SA, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion SpA, LFB SA, Biotest AG, Sanquin, Bio Products Laboratory Ltd, Intas Pharmaceuticals Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA FRACTIONATION MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. ImmunoglobulinsA ((Intravenous immunoglobulins, Subcutaneous immunoglobulins, Other immunoglobulins)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Coagulation FactorsA (Factor VIII, Factor IX, VON Willebrand Factor, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Protease inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA FRACTIONATION MARKET: BY METHOD 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Method
  • 5.2. Centrifugation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Depth Filtration Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Chromatography Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA FRACTIONATION MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Pulmonology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PLASMA FRACTIONATION MARKET: BY END-USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use
  • 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Clinical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PLASMA FRACTIONATION MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Product
    • 8.2.2 By Method
    • 8.2.3 By Application
    • 8.2.4 By End-use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Product
    • 8.3.2 By Method
    • 8.3.3 By Application
    • 8.3.4 By End-use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Product
    • 8.4.2 By Method
    • 8.4.3 By Application
    • 8.4.4 By End-use
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Product
    • 8.5.2 By Method
    • 8.5.3 By Application
    • 8.5.4 By End-use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Product
    • 8.6.2 By Method
    • 8.6.3 By Application
    • 8.6.4 By End-use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PLASMA FRACTIONATION INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Grifols S.A
    • 10.2.2 CSL Limited
    • 10.2.3 Takeda Pharmaceutical Company Limited
    • 10.2.4 Octapharma AG
    • 10.2.5 Kedrion S.P.A
    • 10.2.6 LFB S.A
    • 10.2.7 Biotest AG
    • 10.2.8 Sanquin
    • 10.2.9 Bio Products Laboratory Ltd
    • 10.2.10 Intas Pharmaceuticals Ltd